Patent · US Active

Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics

US12012451B2 · kind B2 · utility

0Cited by
3References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 19, 2020
Grant dateJun 18, 2024
Priority date—
Expiry dateNov 24, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N15/1132
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.